 |
PDBsum entry 5flc
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
615 a.a.
|
|
|
|
|
|
|
|
|
|
|
365 a.a.
|
|
|
|
|
|
|
|
|
|
|
1029 a.a.
|
|
|
|
|
|
|
|
|
|
|
1050 a.a.
|
|
|
|
|
|
|
|
|
|
|
107 a.a.
|
|
|
|
|
|
|
|
|
|
|
317 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Architecture of human mtor complex 1.
|
|
|
Authors
|
|
C.H.Aylett,
E.Sauer,
S.Imseng,
D.Boehringer,
M.N.Hall,
N.Ban,
T.Maier.
|
|
|
Ref.
|
|
Science, 2016,
351,
48-52.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
Target of rapamycin (TOR), a conserved protein kinase and central controller of
cell growth, functions in two structurally and functionally distinct complexes:
TORC1 and TORC2. Dysregulation of mammalian TOR (mTOR) signaling is implicated
in pathologies that include diabetes, cancer, and neurodegeneration. We resolved
the architecture of human mTORC1 (mTOR with subunits Raptor and mLST8) bound to
FK506 binding protein (FKBP)-rapamycin, by combining cryo-electron microscopy at
5.9 angstrom resolution with crystallographic studies of Chaetomium thermophilum
Raptor at 4.3 angstrom resolution. The structure explains how FKBP-rapamycin and
architectural elements of mTORC1 limit access to the recessed active site.
Consistent with a role in substrate recognition and delivery, the conserved
amino-terminal domain of Raptor is juxtaposed to the kinase active site.
|
|
|
|
|
|
|
